Simvastatin (Zocor)

A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.

Also Known As:

Networked: 4980 relevant articles (585 outcomes, 1584 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wachtell, Kristian: 41 articles (01/2022 - 04/2007)
2.	Gerdts, Eva: 40 articles (01/2021 - 04/2007)
3.	Pedersen, Terje R: 38 articles (12/2019 - 01/2003)
4.	Boman, Kurt: 33 articles (12/2019 - 04/2007)
5.	Tershakovec, Andrew M: 32 articles (10/2021 - 10/2006)
6.	Ray, Simon: 32 articles (01/2021 - 04/2007)
7.	Cramariuc, Dana: 26 articles (01/2021 - 02/2008)
8.	Rossebø, Anne B: 25 articles (01/2022 - 04/2007)
9.	Ballantyne, Christie M: 24 articles (12/2016 - 06/2003)
10.	Blazing, Michael A: 23 articles (10/2021 - 11/2003)

Related Diseases

1.	Hypercholesterolemia 11/01/2016 - "Our results suggest that 3 months of simvastatin treatment in a diet-induced hypercholesterolemia rat model alters some tendon mechanical and histological properties, although a strong conclusion in support of improved parameters cannot be drawn. " 06/01/2010 - "Our findings support claims that simvastatin may be beneficial in preserving endothelial function in prediabetic subjects with normo- or mild-to-moderate hypercholesterolemia. " 01/01/1996 - "Higher doses of simvastatin are considerably more effective in the treatment of primary hypercholesterolemia." 10/16/1989 - "Simvastatin appears to be an effective and well-tolerated agent for the treatment of primary hypercholesterolemia and, as further study confirms long-term safety and efficacy, it should become a useful addition to the therapeutic armamentarium." 07/01/1999 - "These results suggest that simvastatin appears to be safe and effective in HD patients with hypercholesterolemia."
2.	Hyperlipidemias (Hyperlipidemia) 11/06/2023 - "Developed as an effective treatment for hyperlipidemia, simvastatin (SIM) is also known for its well-established anti-inflammatory and osteogenic properties, suggesting its potential utility in treating PD. " 06/01/2009 - "In the short-term the combination of diet and simvastatin was effective in lowering hyperlipidemia in children with renal disorders." 03/01/2015 - "The study performed to evaluate the efficacy of Nigella sativa in comparison to simvastatin to treat hyperlipidemia. " 05/01/2008 - "This study suggests for the first time that simvastatin treatment in diabetic patients with hyperlipidemia is associated with an improvement in the heterogeneity of cardiac repolarization. " 02/01/2001 - "Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study."
3.	Dyslipidemias (Dyslipidemia) 02/01/2009 - "These results suggest non-HDL-C, TG (both 50% to 60%), and HDL-C (∼25%) concentrations can be markedly improved by a combination of P-OM3 (4 g/day) and simvastatin (80 mg/day) in subjects with mixed dyslipidemia." 08/01/2014 - "A total of 102 patients with dyslipidemia were treated with simvastatin or placebo during a double-blind, cross-over, placebo-controlled trial. " 03/01/2014 - "Effect of Nigella sativa and Allium sativum coadminstered with simvastatin in dyslipidemia patients: a prospective, randomized, double-blind trial." 09/01/2013 - "This study was designed to compare the efficacy and tolerability of morning and evening doses of controlled-release simvastatin in Korean adults with dyslipidemia. " 07/01/2023 - "We utilized a Western diet-induced dyslipidemia mouse model and divided animals into the following four groups (n = 5 each): the normal chow diet, vehicle control (WD), simvastatin (Sim, 10 mg/kg/day simvastatin; positive control), and GBH (GBH, 300 mg/kg/day) groups. "
4.	Inflammation (Inflammations) 12/26/2010 - "In conclusion, in hyperlipidemic HD patients, simvastatin treatment resulted in a significant reduction in markers of endothelial dysfunction, inflammation, oxidative stress, endothelial cell apoptosis and peripheral blood monocyte stimulation. " 01/01/2022 - "Treatment with 3‑methyladenine, an autophagy inhibitor, completely blocked the protective effects of simvastatin on neutrophils from SP, including the effects of simvastatin on the inhibition of inflammation, oxidative stress and improving cell viability. " 02/01/2024 - "Simvastatin may be helpful in increasing bone regeneration, decreasing inflammation, and soft tissue healing. " 01/01/2017 - "These results suggest that simvastatin treatment restores angiogenic balance and ameliorates inflammation and oxidative stress in a rat model of PE involving ERK/MAPK pathway." 11/01/2008 - "These results suggest that simvastatin ameliorates I/R-induced liver and lung tissue damage by inhibiting the level of inflammation and the apoptotic pathways. "
5.	Atherosclerosis 05/01/1991 - "The results indicate that simvastatin would be effective in the treatment of atherosclerosis." 05/01/2017 - "The present study extensively characterizes the time-dependent plaque composition and functional responses of the atherosclerosis in rabbit iliac artery and its modification by simvastatin. " 12/01/2016 - "Thus, simvastatin was demonstrated to exhibit preventive properties against the formation of atherosclerosis in the atherosclerosis model in the current study, predominantly via its hypolipidemic activity." 12/01/2016 - "The present study was designed to investigate the effect of simvastatin on mouse peritoneal macrophage foam cell formation, the early feature of atherosclerosis, and explore its mechanisms. " 02/04/2004 - "The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging."

Related Drugs and Biologics

1.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2.	Atorvastatin (Lipitor)
3.	Lipids
4.	Ezetimibe (Zetia)
5.	Cholesterol
6.	Pravastatin (Pravachol)
7.	LDL Cholesterol
8.	Rosuvastatin Calcium (Crestor)
9.	oxidized low density lipoprotein
10.	Simvastatin Drug Combination Ezetimibe (Vytorin)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
4.	Secondary Prevention
5.	Ligation